Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Status:
Withdrawn
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This will be a prospective, multi-center, randomized, double-blind, parallel group,
placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic
medication and have at least mild levodopa-induced dyskinesia. Eligible participants will be
randomized to one of three treatment groups to receive adjunctive daily treatment with either
safinamide 100 mg, safinamide 150 mg or placebo in a 1:1:1 ratio. Outcome will be assessed
after 26 weeks of treatment.